InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
tw0122 Free
10/26/23 3:35 PM
profile icon
georgie18 PremiumMember
11/11/21 11:36 AM
profile icon
georgie18 PremiumMember
11/11/21 9:05 AM
profile icon
georgie18 PremiumMember
11/02/21 7:55 AM
profile icon
georgie18 PremiumMember
11/01/21 10:25 AM
profile icon
georgie18 PremiumMember
10/07/21 11:36 AM
profile icon
georgie18 PremiumMember
10/06/21 10:08 AM
profile icon
north40000 PremiumMember
09/30/21 1:05 PM
profile icon
georgie18 PremiumMember
09/24/21 8:01 AM
profile icon
georgie18 PremiumMember
06/26/21 7:34 AM
profile icon
georgie18 PremiumMember
05/14/21 9:42 AM
profile icon
georgie18 PremiumMember
05/12/21 10:25 AM
profile icon
georgie18 PremiumMember
03/22/21 8:19 AM
profile icon
georgie18 PremiumMember
03/01/21 5:56 AM
profile icon
JimsZ Free
02/03/21 10:00 AM
profile icon
JimsZ Free
02/02/21 1:23 PM
profile icon
georgie18 PremiumMember
01/12/21 10:13 AM
profile icon
georgie18 PremiumMember
12/14/20 9:17 AM
profile icon
LiquidPorsche Free
12/01/20 10:57 AM
profile icon
georgie18 PremiumMember
11/30/20 7:07 AM
profile icon
georgie18 PremiumMember
11/12/20 9:47 AM
profile icon
georgie18 PremiumMember
11/11/20 9:12 AM
profile icon
whytestocks Free
11/04/20 10:15 PM
profile icon
georgie18 PremiumMember
11/04/20 11:10 AM
profile icon
georgie18 PremiumMember
10/06/20 11:46 AM
profile icon
LiquidPorsche Free
10/05/20 1:58 PM
profile icon
north40000 PremiumMember
10/01/20 9:04 PM
profile icon
georgie18 PremiumMember
09/29/20 10:08 AM
profile icon
georgie18 PremiumMember
09/15/20 9:27 AM
profile icon
georgie18 PremiumMember
09/03/20 6:45 AM
profile icon
georgie18 PremiumMember
08/18/20 8:18 AM
profile icon
whytestocks Free
08/16/20 9:45 AM
profile icon
ClayTrader Free
08/12/20 5:54 PM
profile icon
georgie18 PremiumMember
08/11/20 6:47 AM
profile icon
georgie18 PremiumMember
08/10/20 9:56 AM
profile icon
georgie18 PremiumMember
08/07/20 6:12 AM
profile icon
georgie18 PremiumMember
08/06/20 8:17 AM
profile icon
north40000 PremiumMember
07/31/20 11:22 PM
profile icon
georgie18 PremiumMember
07/31/20 4:11 PM
profile icon
LiquidPorsche Free
07/31/20 2:13 PM
profile icon
georgie18 PremiumMember
07/31/20 10:01 AM
profile icon
georgie18 PremiumMember
07/23/20 7:50 AM
profile icon
Limey42 Free
04/27/20 11:26 AM
profile icon
DrChess Free
04/27/20 11:05 AM

Catalyst Pharmaceutical Partners (CPRX) RSS Feed

Followers
183
Posters
400
Posts (Today)
0
Posts (Total)
4122
Created
04/23/07
Type
Free
Moderators
Institutional Ownership Percentage:
8/19/19- 60.98%

8/14/19 -60.15%

Shares Purchased this month by Institutions: 19 Million

 

Q2-19 Financial Results

  • Product revenue, net in the second quarter 2019 was $28.8 million
    Reported net income of $11.0 million, or $0.11 per basic and $0.10 per diluted share, in the second quarter of 2019, compared with a net loss of $6.0 million, or $0.06 per basic and diluted share, for the second quarter of 2018.
    Selling, general and administrative expenses for the second quarter of 2019 totaled $9.0 million as compared to $2.6 million in the second quarter of 2018.
    Research and development expenses for the second quarter of 2019 were $4.6 million as compared to $3.7 million for the second quarter of 2018.
    Ended June 30, 2019 with $64.9 million in cash and investments and no funded debt.

Recent Developments and Highlights

  • Initiated commercial launch of Firdapse for LEMS on January 15, 2019.
    Had 409 adult LEMS patients on Firdapse as of June 30, 2019, compared to 337 patients on March 31, 2019.
    As of today, 138 patients previously naïve to any form of 3,4-DAP are enrolled in Catalyst Pathways.
    Amended our Firdapse license agreement to expand the commercial territory to include Japan.
    Global expansion of Firdapse for LEMS underway in Canada and Japan.
    Filed federal lawsuit against U.S. Food and Drug Administration challenging the approval of RuzurgiTM for the treatment of pediatric LEMS patients (ages 6 to under 17).
         Link to Lawsuit filings: https://www.courtlistener.com/docket/15763209/catalyst-pharmaceuticals-inc-v-azar/?order_by=desc&;

Upcoming Milestones

  • Expect to complete enrollment for the MuSK-MG trial in the second half of 2019 and to report top-line results from this trial in the first half of 2020.
    Expect top-line results from Phase 3 trial for CMS in the second half of 2019.
    Expect top-line results for SMA Type 3 proof of concept trial in the first half of 2020.



Clinical Trails Completed
Lambert-Eaton myasthenic Sydrome (Lems) ( Complete )
    Product Result - Firdapse - 
FDA-approved first-line treatment for adults with LEMS

Clinical Trials In Progress:
 Details for CMS - Clinical Trial Link: https://clinicaltrials.gov/ct2/show/NCT02562066?term=Amifampridine+phosphate&cond=CMS&rank=2
     Estimated Primary Completion Date: September 2019
     Estimated Study Completion Date: December 2019
 Details for MuSK-MG - Clinical Trial Link: 
https://www.clinicaltrials.gov/ct2/show/NCT03304054?term=amifampridine&cond=MuSk+MG
     Estimated Primary Completion Date: October 2019
     Estimated Study Completion Date:  December 2019
Neuronal Potassium Channel Blocker(amifampridine)
Most Recent Insider Trading :  6/11/19 - Patrick J Mcenany CEO - Buy 25,000 Shares @ $3.23


Links:
SEC Filings: https://eresearch.fidelity.com/eresearch/evaluate/fundamentals/secFilings.jhtml?stockspage=secFilings&symbols=CPRX

Recent Article Coverage:
August 19, 2019 - Top Ranked Momentum Stocks to Buy for August 19th - https://finance.yahoo.com/news/top-ranked-momentum-stocks-buy-160004065.html?.tsrc=rss
August 16, 2019 - Will Catalyst Pharmaceuticals Continue to Surge Higher? - https://www.nasdaq.com/article/will-catalyst-pharmaceuticals-continue-to-surge-higher-cm1199219
August 13th - The Best of Both Worlds - https://finance.yahoo.com/news/catalyst-pharmaceuticals-inc-nasdaq-cprx-154240541.html?.tsrc=rss


Target Pricing:
https://www.marketbeat.com/stocks/NASDAQ/CPRX/price-target/
Lastest Reports: Aug 08, 2019
Price Target Range: $9.00 - $12.00
New Post